(19)
(11) EP 3 648 587 B8

(12) CORRECTED EUROPEAN PATENT SPECIFICATION
Note: Bibliography reflects the latest situation

(15) Correction information:
Corrected version no 1 (W1 B1)

(48) Corrigendum issued on:
16.10.2024 Bulletin 2024/42

(45) Mention of the grant of the patent:
29.05.2024 Bulletin 2024/22

(21) Application number: 18743421.2

(22) Date of filing: 05.07.2018
(51) International Patent Classification (IPC): 
A01K 67/027(2024.01)
C12N 15/85(2006.01)
(52) Cooperative Patent Classification (CPC):
A01K 67/0276; A01K 67/0278; C07K 2317/92; A01K 67/027; C07K 16/00; A01K 2217/072; A01K 2217/075; A01K 2217/15; A01K 2227/105; A01K 2267/01; C07K 2317/21; C07K 2317/24; C07K 2317/31; C07K 2317/515; C07K 2317/55; C07K 2317/14
(86) International application number:
PCT/EP2018/068309
(87) International publication number:
WO 2019/008123 (10.01.2019 Gazette 2019/02)

(54)

CELLS, VERTEBRATES, POPULATIONS & METHODS

ZELLEN,VERTEBRATEN,POPULATIONEN UND VERFAHREN

CELLULES, VERTEBRATES,POPULATIONS ET METHODES


(84) Designated Contracting States:
AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

(30) Priority: 07.07.2017 GB 201710984

(43) Date of publication of application:
13.05.2020 Bulletin 2020/20

(60) Divisional application:
24178098.0 / 4410986

(73) Proprietor: Kymab Limited
Cambridge CB22 3AT (GB)

(72) Inventors:
  • LEE, E-Chiang
    Cambridge, Cambridgeshire CB22 3AT (GB)
  • WANG, Wei
    Cambridge, Cambridgeshire CB22 3AT (GB)
  • BLACKWOOD, John Kenneth
    Cambridge CB22 3AT (GB)
  • MAGLIOZZI, Roberto
    Cambridge CB22 3AT (GB)
  • WOOD, Andrew
    Cambridge, CB22 3AT (GB)

(74) Representative: CMS Cameron McKenna Nabarro Olswang LLP 
Cannon Place 78 Cannon Street
London EC4N 6AF
London EC4N 6AF (GB)


(56) References cited: : 
EP-A1- 2 147 594
WO-A2-2006/117699
US-A1- 2011 195 454
US-A1- 2013 263 292
WO-A1-2014/130690
US-A1- 2006 015 957
US-A1- 2012 021 409
US-A1- 2018 298 112
   
  • ODEGARD VALERIE H ET AL: "Targeting of somatic hypermutation", NATURE REVIEWS IMMUNOLOGY, NATURE PUBLISHING GROUP UK, LONDON, vol. 6, no. 8, 1 August 2006 (2006-08-01), pages 573 - 583, ISSN: 1474-1733, DOI: 10.1038/NRI1896
  • BETZ A G ET AL: "Elements regulating somatic hypermutation of an immunoglobulin @k gene: Critical role for the intron enhancer/matrix attachment region", CELL, ELSEVIER, AMSTERDAM NL, vol. 77, no. 2, 22 April 1994 (1994-04-22), pages 239 - 248, ISSN: 0092-8674, [retrieved on 19940422], DOI: 10.1016/0092-8674(94)90316-6
  • BETZ A G ET AL: "Elements regulating somatic hypermutation of an immunoglobulin @k gene: Critical role for the intron enhancer/matrix attachment region", CELL, ELSEVIER, AMSTERDAM NL, vol. 77, no. 2, 22 April 1994 (1994-04-22), pages 239 - 248, XP024245265, ISSN: 0092-8674, [retrieved on 19940422], DOI: 10.1016/0092-8674(94)90316-6
  • ODEGARD VALERIE H ET AL: "Targeting of somatic hypermutation", NATURE REVIEWS IMMUNOLOGY, NATURE PUBLISHING GROUP UK, LONDON, vol. 6, no. 8, 1 August 2006 (2006-08-01), pages 573 - 583, XP002556635, ISSN: 1474-1733, DOI: 10.1038/NRI1896
  • MATTHEW A. INLAY ET AL: "Critical roles of the immunoglobulin intronic enhancers in maintaining the sequential rearrangement of IgH and Igk loci", THE JOURNAL OF EXPERIMENTAL MEDICINE, vol. 203, no. 7, 10 July 2006 (2006-07-10), US, pages 1721 - 1732, XP055516424, ISSN: 0022-1007, DOI: 10.1084/jem.20052310
  • DIAZ M ET AL: "Somatic immunoglobulin hypermutation", CURRENT OPINION IN IMMUNOL, ELSEVIER, OXFORD, GB, vol. 14, no. 2, 1 April 2002 (2002-04-01), pages 235 - 240, XP004340052, ISSN: 0952-7915, DOI: 10.1016/S0952-7915(02)00327-8
  • T. PERLOT ET AL: "Elucidation of IgH intronic enhancer functions via germ-line deletion", PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, vol. 102, no. 40, 4 October 2005 (2005-10-04), pages 14362 - 14367, XP055516419, ISSN: 0027-8424, DOI: 10.1073/pnas.0507090102
  • WINTER D B ET AL: "Insertion of 2 kb of bacteriophage DNA between an immunoglobulin promoter and leader exon stops somatic hypermutation in a kappa transgene", MOLECULAR IMMUNOLOGY, PERGAMON, GB, vol. 34, no. 5, 1 April 1997 (1997-04-01), pages 359 - 366, XP002556634, ISSN: 0161-5890, [retrieved on 19971010], DOI: 10.1016/S0161-5890(97)00073-4
   
Note: Within nine months from the publication of the mention of the grant of the European patent, any person may give notice to the European Patent Office of opposition to the European patent granted. Notice of opposition shall be filed in a written reasoned statement. It shall not be deemed to have been filed until the opposition fee has been paid. (Art. 99(1) European Patent Convention).